List view / Grid view
13 May 2014 | By GlaxoSmithKline
GlaxoSmithKline announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome...
13 May 2014 | By Johnson & Johnson
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide...
12 May 2014 | By Boehringer Ingelheim
In order to add to scientific and medical progress, Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug development program...
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
6 May 2014 | By Lundbeck
H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
6 May 2014 | By Red Door Communications
New evidence published to coincide with the International Liver Meeting showing the potential for elimination of hepatitis C across 15 countries by 2030...
2 May 2014 | By Merck
MSD and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...
1 May 2014 | By Fibrotech Therapeutics Pty Ltd
Fibrotech announced that it has reached an agreement with Shire plc, under which Shire has agreed to purchase Fibrotech for an upfront payment of $75M...
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
30 April 2014 | By Teva
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties...
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
28 April 2014 | By GlaxoSmithKline
GlaxoSmithKline and Medicines for Malaria Venture announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine...
24 April 2014 | By Biogen Idec
Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement...
24 April 2014 | By Boehringer Ingelheim
Hydra Biosciences, Inc. and Boehringer Ingelheim jointly announced that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors...
23 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site...
